Abstract:The scale of the humanitarian and economic impact of the COVID-19 pandemic provided insights into the landscape of vaccine development. The magnitude of the Coronavirus and its variants—over 260 million cases and more than five million deaths by early 2022—has called overdue attention to how we foster investment in the development of new vaccines against emerging pathogens. Vaccines serve both as cost-effective tools to prevent outbreaks of infectious diseases and as mechanisms to shorten their duration and lessen their socio-economic impact. Yet, absent a pandemic or other large-scale public health crisis, most types of vaccine research and development (R&D) remain largely untapped.This Article argues that ongoing legal and policy debates about the problem of incentivizing robust levels of vaccine innovation routinely fail to acknowledge the role that the tax system can play in this area. Historically, policymakers have attempted to promote investment in vaccine R&D through the use of traditional innovation levers. Of these traditional innovation mechanisms are intellectual property (“IP”) and non-IP policy tools that allocate proprietary price and reward successful R&D, respectively. Patents, grants, regulatory vouchers, and— to a lesser extent—prizes are the limited arsenal of innovation policies that incidentally also aim to instigate vaccine development. Much less attention, however, has been paid to the idiosyncratic hurdles of vaccine research and the role of fiscal policy in spurring investments in vaccine-specific R&D. To fill this gap, this Article develops a general normative theory: the market-based characteristics of fiscal incentives make them especially well-suited to encourage investment in vaccine innovation, thereby contributing to increasing preparedness. Alas, we demonstrate that current design of tax incentives drives research away from vaccine and towards more profitable mainstream discoveries. Yet, when designed properly, fiscal apparatuses can offer several unique advantages in the vaccine context: the ability to harness private market mechanisms ex ante to economize on resources, administrative costs, regulatory capture, and informational problems. Building on this analytical premise, this Article offers a novel framework for optimal fiscal policy that spurs investment in vaccine R&D in a more predictable and streamlined fashion, while lowering risk associated with the vaccine development processes. Additionally, we illustrate how fiscal policy can be used as an effective tool for equitable distribution of the cost of developing vaccines for emerging diseases, which to date has never been fully explored. While focused on the tax system, our proposed approach is illustrative of, and contributes to, the growing call for “innovation policy pluralism” as defined by Professors Hemel and Ouellette in their work on the synergistic combination of different types of incentives to innovation. Finally, our proposed fiscal policy offers a blueprint for possible interventions in other traditionally underfunded areas in pharmaceutical research.

Gluten-free diet in patients with dermatitis herpetiformis: not only a matter of skin.

FECCA-a new access algorithm for an ATM ring network with destination removal

European priority review vouchers for neglected disease product development

Impact of Priority Review Voucher Eligibility on Research and Development of Medical Countermeasures

The United States Food and Drug Administration (FDA) regulatory response to combat neglected tropical diseases (NTDs): A review

Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development

[The preventive effect of ephedrine on the syncopal accidents due to quinidine (Study of 300 cases of regularization of auricular fibrillation)].

Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges

Anti-tuberculosis treatment strategies and drug development: challenges and priorities

Comparing research and development, launch, and scale up timelines of 18 vaccines: lessons learnt from COVID-19 and implications for other infectious diseases

Reliably Assessing "Value" While Addressing High Prices

Expediting treatments in the 21st century: orphan drugs and accelerated approvals

Factors, enablers and challenges for COVID-19 vaccine development

Pharmaceutical policy and innovation for rare diseases: A narrative review

Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response

Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges

Bending the Curve Through Innovations to Overcome Persistent Obstacles in HIV Prevention and Treatment

Tax Policy and Pharmaceutical Innovation

Accelerating R&amp;D for Emerging Infectious Diseases: Lessons Learnt From Ebola

A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships

Global Disparities in Access to Vaccine Clinical Trials: A Review of the Literature